Scleritis Market to Reach USD 2.2 Billion by 2034

Scleritis is a serious inflammatory disease of the sclera, the white outer coating of the eye. It is often associated with systemic autoimmune conditions such as rheumatoid arthritis, granulomatosis with polyangiitis, lupus, and inflammatory bowel disease. Symptoms include severe ocular pain, redness, and potential vision loss if untreated.

Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72281

Unlike episcleritis, scleritis is more severe and frequently requires systemic immunosuppressive therapy or biologics. With the global rise of autoimmune and inflammatory diseases, the scleritis market is gaining attention, especially with advancements in biologics, corticosteroid-sparing therapies, and targeted drug delivery systems.

Market Overview
• Market Size (2024): USD 1.1 billion
• Forecast (2034): USD 2.2 billion
• CAGR (2025-2034): 7.3%

Key Highlights:
• Increasing incidence of autoimmune and systemic inflammatory diseases fueling prevalence.
• Expansion of biologic therapies (anti-TNF, anti-IL agents) in ophthalmic inflammation.
• Growing use of corticosteroids and immunosuppressive drugs as first-line treatments.
• Rising focus on precision medicine and early diagnosis.

Segmentation Analysis
By Treatment Type:
• Corticosteroids (oral, topical, injectable)
• Immunosuppressants (methotrexate, azathioprine, mycophenolate)
• Biologics (adalimumab, infliximab, emerging IL inhibitors)
• NSAIDs (supportive role, episcleritis overlap)
• Surgical (rare, for complications such as scleral thinning)

By Indication:
• Anterior Scleritis (largest share)
• Posterior Scleritis
• Necrotizing Scleritis
• Scleritis Associated with Autoimmune Disease

By End Use:
• Hospitals & Specialty Eye Clinics
• Ambulatory Surgical Centers
• Academic & Research Institutes
• Retail & Online Pharmacies

Segmentation Summary:
Corticosteroids and immunosuppressants dominate today's market, but biologics are the fastest-growing segment, offering targeted therapy for severe, refractory cases.

Explore Full Report here: https://exactitudeconsultancy.com/reports/72281/scleritis-market

Regional Analysis
North America
• Largest market (~42% share in 2024).
• High autoimmune disease prevalence and strong adoption of biologics.
• FDA approvals for uveitis and related conditions benefiting scleritis management.
Europe
• ~30% share.
• Germany, UK, and France lead in immunology-driven ophthalmic research.
• EMA support for biologics in autoimmune ocular disease.
Asia-Pacific
• Fastest-growing region, CAGR ~8.5%.
• Increasing cases of autoimmune disorders in India, China, and Japan.
• Expanding access to immunosuppressants and biologics.
Latin America
• Brazil and Mexico improving access to specialty care and biologic therapies.
Middle East & Africa
• GCC countries advancing ophthalmology infrastructure.
• Higher unmet need in lower-income regions due to limited biologic availability.
Regional Summary:
North America and Europe dominate adoption, while Asia-Pacific is projected to expand fastest, supported by rising autoimmune disease burden and healthcare investment.

Market Dynamics
Key Growth Drivers:
• Increasing global prevalence of autoimmune conditions linked to scleritis.
• Rising use of biologics (adalimumab, infliximab) for refractory ocular inflammation.
• Advances in diagnostic imaging (ultrasound biomicroscopy, OCT) for posterior scleritis.
• Growing ophthalmology specialization in emerging markets.

Key Challenges:
• High treatment cost of biologics.
• Side effects of long-term corticosteroid and immunosuppressant use.
• Underdiagnosis and misdiagnosis of posterior scleritis.
• Uneven access to advanced therapies in developing regions.

Latest Trends:
• Development of next-generation IL-6 and JAK inhibitors.
• Research into biologic eye drops and targeted delivery systems.
• Integration of AI-based imaging for early and accurate detection.
• Patient-centric models combining rheumatology and ophthalmology care.

Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=72281

Competitor Analysis
Major Players in the Market:
• AbbVie Inc. (Humira - adalimumab)
• Novartis AG
• F. Hoffmann-La Roche Ltd.
• Regeneron Pharmaceuticals, Inc.
• Santen Pharmaceutical Co., Ltd.
• Bausch + Lomb
• Johnson & Johnson Vision
• Pfizer Inc.
• Sun Pharmaceutical Industries Ltd.
• Alimera Sciences

Competitive Summary:
AbbVie leads with adalimumab for severe uveitis and ocular inflammatory disease, widely used off-label for scleritis. Novartis and Roche are investing in next-gen biologics, while Regeneron is advancing anti-inflammatory ocular therapies. Traditional ophthalmic players (Santen, Bausch, J&J Vision) provide corticosteroid and immunosuppressive solutions.

Conclusion
The Scleritis Market, valued at USD 1.1 billion in 2024, is projected to reach USD 2.2 billion by 2034, growing at a CAGR of 7.3%.

Key Takeaways:
• Autoimmune-driven scleritis is the largest contributor to market growth.
• Corticosteroids and immunosuppressants dominate today, but biologics are the fastest-growing category.
• North America and Europe lead adoption, while Asia-Pacific grows fastest.
• Advances in precision biologics, AI diagnostics, and multidisciplinary care will transform management.

Over the next decade, the scleritis market will move beyond traditional corticosteroids toward targeted, long-acting biologic and regenerative solutions, improving outcomes for patients with vision-threatening ocular inflammation.

This report is also available in the following languages : Japanese (強膜炎市場), Korean (강막염 시장), Chinese (巩膜炎市场), French (Marché de la sclérite), German (Skleritis-Markt), and Italian (Mercato della sclerite), etc.

Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/72281/scleritis-market#request-a-sample

Our More Reports:

Non-Small Cell Lung Cancer Market
https://exactitudeconsultancy.com/reports/72857/non-small-cell-lung-cancer-market

Lipid CMO Market
https://exactitudeconsultancy.com/reports/72858/lipid-cmo-market

Novel T-Cell Immunotherapy Market
https://exactitudeconsultancy.com/reports/72859/novel-t-cell-immunotherapy-market

About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/

https://www.thehealthanalytics.com/

https://www.analytica.global/

https://www.marketintelligencedata.com/

https://www.marketinsightsreports.com/

https://exactitudeconsultancy.com/

Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com

This release was published on openPR.